MD Anderson Cancer Center
Houston, Texas, United States
Dr. Burger’s research focus is to understand the mechanism that malignant B lymphocytes utilized within the tissue microenvironment to receive growth and survival signals. His research focus has been chronic lymphocytic leukemia (CLL) and the role of lymphoma-associated macrophages (LAP), which is termed nurselike cellsv(NLC), in CLL pathobiology. NLC activate BCR B cell receptor (BCR) signaling pathway, and we have characterized mechanism of BCR activation in CLL and the effects of BCR signaling blockade, using kinase inhibitors that target BCR-related kinase, such as SYK, BTK and P13K delta. We also have characterized BCR downstream signaling as well as interactions between CLL and T cells that support the growth of the malignant B cell clone. These topics are also tested in translational studies that are part of clinical trials, where effects of kinase inhibitors targeting BCR signaling are tested in patient specimen. His clinical research interest is to advance the use of novel agents in CLL therapy by developing innovative combination and limited-duration therapy approaches.
Disclosure information not submitted.
Friday, October 21, 2022
1:10 PM – 2:35 PM
Friday, October 21, 2022
1:15 PM – 1:35 PM
Friday, October 21, 2022
2:15 PM – 2:35 PM